Fibrocell Science Inc (FCSC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
54
About the Report
About the Report
Summary
Fibrocell Science Inc (Fibrocell Science) is an autologous cell and gene therapy company which discovers and develops therapies for diseases affecting the skin and connective tissue. The company's product pipeline comprises FCX-007, a lead candidate for the treatment of recessive dystrophic epidermolysis bullosa; FCX-013 for linear scleroderma; and a research program for the treatment of arthritis and related conditions. Fibrocell Science utilizes its proprietary autologous fibroblast technology to develop personalized biologics for skin diseases. It has a manufacturing facility in Exton, Pennsylvania; and operates along with its subsidiaries in the US and Switzerland. Fibrocell Science is headquartered in Exton, Pennsylvania, the US.
Fibrocell Science Inc (FCSC)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Fibrocell Science Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Fibrocell Science Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Fibrocell Science Inc, Medical Devices Deals, 2012 to YTD 2018 10
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Fibrocell Science Enters into Agreement with Intrexon 12
Fibrocell Science Enters Into Co-Development Agreement With Intrexon 13
Fibrocell Science And Intrexon Expand Co-Development Agreement For Potential New Class Of Therapeutics 14
Fibrocell Science Amends Co-Development Agreement with Intrexon 15
Licensing Agreements 16
Fibrocell Science Enters into Licensing Agreement with Intrexon 16
Fibrocell Science Enters into Licensing Agreement with University of California to Advance the Development of Personalized Cell Therapies 18
Fibrocell Science Enters Into Licensing Agreement With University of California 19
Equity Offering 20
Fibrocell Science Raises USD4 Million in Direct Offering of Shares 20
Fibrocell Science Raises USD6 Million in Private Placement of Shares 22
Fibrocell Science Raises Public Offering of Shares and Warrants for USD10.5 Million 23
Fibrocell Science Raises USD8 Million in Private Placement of Series A Preferred Stock and Warrants 25
Fibrocell Science to Raise up to USD50 Million in Public Offeirng of Shares 26
Fibrocell Raises USD17.3 Million in Public Offering of Shares 27
Fibrocell Science Completes Underwriters Exercise Of Partial Over-Allotment Option Of Public Offering Of Shares For USD 50.5 Million 29
Fibrocell Science Completes Private Placement Of Shares For USD 45 Million 31
Fibrocell Science Completes Second Tranche Of Private Placement For USD 5.8 Million 33
Debt Offering 34
Fibrocell Science Raises USD18.1 Million in Private Placement of Notes and Warrants 34
Acquisition 35
Rohto Pharma Completes Acquisition Of 57% Stake In Agera Labs, Skincare Company 35
Fibrocell Science Inc-Key Competitors 36
Fibrocell Science Inc-Key Employees 37
Fibrocell Science Inc-Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Joint Venture 38
Recent Developments 39
Financial Announcements 39
Aug 09, 2018: Fibrocell Reports second quarter 2018 financial results and recent highlights 39
May 10, 2018: Fibrocell Reports First Quarter 2018 Financial Results and Recent Highlights 41
Mar 19, 2018: Fibrocell Announces 2017 Financial Results 43
Nov 13, 2017: Fibrocell Reports Third Quarter 2017 Financial Results and Recent Highlights 45
Aug 09, 2017: Fibrocell Reports Second Quarter 2017 Financial Results and Recent Highlights 47
May 10, 2017: Fibrocell Reports First Quarter 2017 Financial Results and Recent Operational Highlights 48
Mar 09, 2017: Fibrocell Reports 2016 Financial Results and Recent Operational Highlights 49
Product Approvals 51
Feb 05, 2018: Fibrocell Announces Submission of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Localized Scleroderma 51
Jun 12, 2017: Fibrocell Receives Rare Pediatric Disease Designation from FDA for FCX-013 for Treatment of Localized Scleroderma 52
Clinical Trials 53
May 09, 2017: Fibrocell and Intrexon Announces Data on FCX-013 at the 20th Annual Meeting of the American Society of Gene & Cell Therapy 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54
List of Figure
List of Figures
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Fibrocell Science Inc, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Fibrocell Science Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Fibrocell Science Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Fibrocell Science Inc, Medical Devices Deals, 2012 to YTD 2018 10
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Fibrocell Science Enters into Agreement with Intrexon 12
Fibrocell Science Enters Into Co-Development Agreement With Intrexon 13
Fibrocell Science And Intrexon Expand Co-Development Agreement For Potential New Class Of Therapeutics 14
Fibrocell Science Amends Co-Development Agreement with Intrexon 15
Fibrocell Science Enters into Licensing Agreement with Intrexon 16
Fibrocell Science Enters into Licensing Agreement with University of California to Advance the Development of Personalized Cell Therapies 18
Fibrocell Science Enters Into Licensing Agreement With University of California 19
Fibrocell Science Raises USD4 Million in Direct Offering of Shares 20
Fibrocell Science Raises USD6 Million in Private Placement of Shares 22
Fibrocell Science Raises Public Offering of Shares and Warrants for USD10.5 Million 23
Fibrocell Science Raises USD8 Million in Private Placement of Series A Preferred Stock and Warrants 25
Fibrocell Science to Raise up to USD50 Million in Public Offeirng of Shares 26
Fibrocell Raises USD17.3 Million in Public Offering of Shares 27
Fibrocell Science Completes Underwriters Exercise Of Partial Over-Allotment Option Of Public Offering Of Shares For USD 50.5 Million 29
Fibrocell Science Completes Private Placement Of Shares For USD 45 Million 31
Fibrocell Science Completes Second Tranche Of Private Placement For USD 5.8 Million 33
Fibrocell Science Raises USD18.1 Million in Private Placement of Notes and Warrants 34
Rohto Pharma Completes Acquisition Of 57% Stake In Agera Labs, Skincare Company 35
Fibrocell Science Inc, Key Competitors 36
Fibrocell Science Inc, Key Employees 37
Fibrocell Science Inc, Subsidiaries 38
Fibrocell Science Inc, Joint Venture 38
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.